NxStage Announces CE Mark Approval, First Clinical Use of its Single Needle for Dialysis Patients

 NxStage Announces CE Mark Approval, First Clinical Use of its Single Needle
                            for Dialysis Patients

Elegant Solution Enhances Company's Recent Nocturnal Clearance in Europe

PR Newswire

LAWRENCE, Mass., Feb. 25, 2013

LAWRENCE, Mass., Feb. 25, 2013 /PRNewswire/ --NxStage® Medical, Inc. (Nasdaq:
NXTM), a leading manufacturer of innovative dialysis products, today announced
its single needle technology, OneSite™, has received CE Mark approval. In
addition, initial patient experiences using this new product have demonstrated
its benefits for dialysis patients.

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO)

The OneSite employs a revolutionary dual lumen needle design with a
buttonhole approach to cannulation.The combination of single site and
buttonhole access greatly reduces the challenges of self cannulation.Having a
single site also enhances safety by having the machine alarm upon access
dislodgement during treatment, thus helping prevent adverse events associated
with Venous Needle Dislodgement (VND).

As the requirement for certain medical devices to be sold in the European
Union, this CE Mark approval will enable NxStage to make OneSite available in
countries where it currently distributes its products, including the United
Kingdom, the Nordic countries, Benelux, France,and Italy. Separately, NxStage
has also received approval to market this product in Canada.

"CE Mark approval for OneSite is another significant milestone that
illustrates the success of our innovation strategy. It represents a meaningful
step forward in advancing the care of dialysis patients and will enhance the
success of our recent nocturnal approval for the NxStage System One in
Europe," said Jeffrey Burbank, Chief Executive Officer, NxStage Medical, Inc.
"Building on our breadth of technology and expertise in fistula needles, we're
bringing to market an elegant single needle solution that does not have the
complexity and complications of other common approaches." 

About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis
system cleared for home use by theU.S. Food & Drug Administration(FDA). The
System One also has a CE mark and has been cleared by Health Canada. Its
simplicity and revolutionary size (just over a foot tall) provide convenient
use in patients' homes and give patients the freedom to travel with their
therapy. Unlike conventional hemodialysis systems, the System One requires no
special infrastructure to operate. Under the guidance of their physician,
patients can use the NxStage System One, with their trained partners, where,
how and when it best meets their needs, at home or on the road.

About NxStage Medical Inc.
NxStage is a medical device company, headquartered in Lawrence, MA, USA, which
develops, manufactures, and markets innovative systems for the treatment of
end-stage renal disease (ESRD), and acute kidney failure. The System One home
hemodialysis device developed by NxStage is the only FDA approved portable
hemodialysis machine cleared for home use. For more information on NxStage, or
NxStage products, visit, http://www.nxstage.com.

Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements contained in
this release that are not clearly historical in nature are forward-looking,
and the words "anticipate," "believe," "expect," "estimate," "plan," and
similar expressions are generally intended to identify forward-looking
statements. Actual results may differ materially from those indicated by these
forward-looking statements as a result of various important factors including
those that are discussed in NxStage's filings with the Securities and Exchange
Commission, including the Quarterly Report on Form 10-Q for the quarter ended
September 30, 2012. NxStage is under no obligation to (and expressly disclaims
any such obligation to) update or alter its forward-looking statements,
whether as a result of new information, future events or otherwise.

CONTACT: NxStage Medical, Inc., ksheppard@nxstage.com

SOURCE NxStage Medical, Inc.

Website: http://www.nxstage.com
Contact: Kristen Sheppard, +1-978-332-5923